A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours
1996

Concomitant Resistance in Murine Tumours

Sample size: 90 publication Evidence: moderate

Author Information

Author(s): M Franco, OD Bustuoabad, PD di Gianni, A Goldman, CD Pasqualini, RA Ruggiero

Primary Institution: Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, Buenos Aires, Argentina

Hypothesis

Can immunogenic tumours induce a form of concomitant resistance similar to that demonstrated for non-immunogenic tumours?

Conclusion

The study suggests that both immunogenic and non-immunogenic tumours can induce a common serum-mediated mechanism of concomitant resistance at late stages of tumour development.

Supporting Evidence

  • Two peaks of concomitant resistance were detected during tumour development.
  • The first peak was tumour specific and T-cell dependent, while the second was non-specific and thymus independent.
  • Serum from tumour-bearing mice exhibited growth-inhibitory activity on tumour cells in vitro.
  • The intensity of the second peak of concomitant resistance correlated with serum inhibitory activity.

Takeaway

When mice have one tumour, they can sometimes fight off a second one, even if it's a different type. This study found that both types of tumours can help mice resist new tumours later on.

Methodology

The study involved various immunisation assays and tumour implantation in BALB/c mice, with subsequent analysis of serum factors and tumour growth.

Limitations

The study primarily focused on murine models, which may not fully translate to human conditions.

Participant Demographics

BALB/c mice of both sexes, aged 2-4 months.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication